CALDERWOOD & HARKNESS LLP Attorneys at Law
1735 Market Street, Suite 3100 Philadelphia, Pennsylvania 19103 Telephone: (215) 564-8800
CONFIDENTIAL — ATTORNEY-CLIENT PRIVILEGED / ATTORNEY WORK PRODUCT NOT TO BE DISCLOSED WITHOUT PRIOR WRITTEN CONSENT OF CALDERWOOD & HARKNESS LLP
Matter Number: 1018-00009 Report Period: Q1 2024 (January 1, 2024 – March 31, 2024) Report Date: April 2, 2024 Status: FINAL — MATTER CLOSED
TO: Marcus Whitfield, Vice President, Global Tax, Penterra Pharmaceuticals Corp.
CC: Deborah Staines, General Counsel, Penterra Pharmaceuticals Corp. Rajesh Iyer, Chief Financial Officer, Penterra Pharmaceuticals Corp. Catherine Falk, Chief Executive Officer, Penterra Pharmaceuticals Corp.
FROM: Leonard Cross, Responsible Partner, Tax Department, Calderwood & Harkness LLP Sylvia Hartwell, Billing Partner, Tax Department, Calderwood & Harkness LLP
RE: Final Quarterly Status Report — IRS Transfer Pricing Examination Defense, Penterra Pharmaceuticals Corp. (EIN: 22-3741856), Tax Years 2017–2020, IRS Exam Team LB&I-NE-TP-2022-00641
Right-click to update Table of Contents
I. EXECUTIVE SUMMARY
This report constitutes the final quarterly status report submitted by Calderwood & Harkness LLP ("C&H") in connection with the defense of Penterra Pharmaceuticals Corp. ("PPC" or the "Company") in the Internal Revenue Service ("IRS") transfer pricing examination covering tax years 2017 through 2020. As set forth in detail below, the examination has been resolved in full, and the matter is now closed.
On March 15, 2024, IRS Appeals Officer Noreen Castañeda issued a formal settlement offer to PPC. Following a thorough analysis of the settlement terms and their financial implications, PPC management approved acceptance of the settlement on March 21, 2024, and C&H transmitted the formal acceptance letter to Appeals Officer Castañeda on March 22, 2024. The IRS Form 906 Closing Agreement memorializing the settlement was executed on March 29, 2024, thereby formally closing the examination for all four tax years at issue (2017, 2018, 2019, and 2020).
The settlement achieved an exceptionally favorable outcome for PPC. The key metrics of the resolution are as follows:
• Total settlement adjustment: $47.6 million across all four tax years, representing only 12.51% of the IRS's net proposed adjustment of $380.4 million — an 87.49% reduction from the IRS's position.
• Full penalty abatement: The IRS's proposed IRC § 6662(e) substantial valuation misstatement penalty of approximately $15.98 million was fully abated. Appeals accepted PPC's reasonable-cause defense and the adequacy of PPC's contemporaneous transfer pricing documentation as establishing penalty protection under IRC § 6662(e)(3)(B).
• Total cash cost to PPC: Approximately $12.84 million, comprised of $10.0 million in additional federal income tax (computed at the 21% corporate rate on the $47.6 million adjustment) and an estimated $2.84 million in underpayment interest. No penalties are payable.
• Total savings versus fully proposed adjustment: Approximately $83.02 million, representing an 86.6% reduction from the IRS's total proposed exposure of $95.86 million (consisting of proposed tax of $79.88 million plus proposed penalties of $15.98 million).
• Total professional fees for the engagement: Approximately $8,325,420, consisting of $5,837,420 in C&H legal fees, $2,146,800 in expert fees paid to Whitmore Valuation Group LLC, and approximately $341,200 in coordination fees paid to Thornbury & Keogh (Irish tax advisors).
• Total all-in cost to PPC: Approximately $21,165,420, inclusive of settlement costs and all professional fees incurred over the full duration of the engagement.
This report provides a comprehensive summary of the activities undertaken during Q1 2024, the final settlement terms, a full examination chronology, a financial summary, post-closure action items, and a roster of key personnel involved in the matter.
II. MATTER BACKGROUND AND SCOPE
A. Client Overview
Penterra Pharmaceuticals Corp. is a Delaware corporation, publicly traded on the Nasdaq Stock Market under the ticker symbol "PPCA," with its principal executive offices located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is a specialty pharmaceutical and biotechnology company with therapeutic franchises concentrated in oncology, immunology, and rare-disease therapeutics. For fiscal year 2020, PPC reported total revenue of approximately $6.82 billion, pre-tax income of approximately $1.47 billion, and employed approximately 14,500 individuals worldwide.
PPC's global operations include significant intellectual property development activities and a substantial international footprint. In 2012, PPC established Penterra Biopharma International DAC ("PBI"), an Irish designated activity company incorporated on March 15, 2012, as the Company's principal international intellectual property holding and commercialization entity. PBI is domiciled in Dublin, Ireland, and maintains its offices at Sandyford Business Park. As of the examination period, PBI employed approximately 185 individuals and operated with a high degree of operational autonomy, including independent pricing decisions across 68 country markets.
B. Commencement of the IRS Examination
On May 16, 2022, the IRS Large Business & International Division ("LB&I") opened an examination of PPC's federal income tax returns (Forms 1120) for tax years 2017, 2018, 2019, and 2020 via issuance of Letter 2205-A (Examination Notification). The examination was assigned to the Northeast Transfer Pricing Practice Area under case reference LB&I-NE-TP-2022-00641.
The IRS examination team consisted of the following personnel:
• Gerald Meskill, Supervisory Revenue Agent / Team Manager
• Patricia Dunleavy, Lead Revenue Agent
• Dr. Alan Washburne, IRS Economist
• Franklin Rosario, Attorney-Advisor, Office of Chief Counsel
• Donna Hirabayashi, Senior Counsel, Office of Chief Counsel
The examination focused on PPC's transfer pricing methodology as applied to its Irish intellectual-property-holding structure. Specifically, the IRS challenged:
(1) The cost-sharing arrangement between PPC and PBI, pursuant to which PBI participated in funding PPC's ongoing research and development activities under a qualified cost-sharing arrangement ("CSA") established effective July 1, 2012;
(2) The intercompany royalty rates charged by PPC to PBI for PBI's license to exploit certain legacy intellectual property that pre-dated the CSA (the "Legacy IP Royalty"); and
(3) The platform contribution transaction ("PCT") payment made by PBI to PPC at the inception of the CSA, and the valuation of the pre-existing intangible property contributed by PPC to the CSA.
C. Engagement of Calderwood & Harkness LLP
C&H was engaged by PPC to serve as lead outside counsel for the examination defense. The engagement letter was executed on June 2, 2022, and IRS Form 2848 (Power of Attorney and Declaration of Representative) was filed with the IRS on June 8, 2022, covering the following C&H attorneys: Leonard Cross, Sylvia Hartwell, Garrett Simmons, and Leila Nazari.
In addition to C&H's engagement, Whitmore Valuation Group LLC ("WVG") was retained as the Company's independent economic expert to provide economic analysis, transfer pricing benchmarking, and valuation services in connection with the examination defense. WVG was retained under a Kovel arrangement to ensure that its analyses and communications with C&H would be protected by the attorney-client privilege. The Kovel letter (reference 1018-00009-KV) was executed on June 20, 2022. The WVG engagement was led by Dr. Helena Vasquez, Managing Director and Lead Economist, with support from Dr. Rohan Chakrabarti, Senior Director.
PPC was not enrolled in the IRS Compliance Assurance Process ("CAP") for any of the tax years at issue, which meant that the examination proceeded under the standard LB&I examination protocols.
D. Examination Through Q4 2023
The examination proceeded through a series of phases over approximately twenty-two months, beginning with the opening conference in June 2022 and culminating in the filing of PPC's formal Protest in December 2023. During the active examination phase (June 2022 through September 2023), the IRS exam team issued a total of 47 Information Document Requests ("IDRs"), each of which was timely responded to by C&H in coordination with PPC's in-house tax team and WVG.
On October 12, 2023, the IRS exam team issued a Notice of Proposed Adjustment ("NOPA") for all four tax years, proposing a net aggregate adjustment of $380.4 million to PPC's taxable income, together with a proposed IRC § 6662(e) substantial valuation misstatement penalty of approximately $15.98 million. On November 8, 2023, the IRS issued the 30-Day Letter providing PPC with the opportunity to file a formal administrative Protest and request a hearing before the IRS Office of Appeals.
C&H filed PPC's formal Protest on December 22, 2023, challenging the IRS's proposed adjustments on all grounds and requesting assignment of the case to the Office of Appeals. The Protest, accompanied by five supporting exhibits (Exhibits A through E), set forth PPC's legal and economic arguments in detail, including the results of WVG's independent economic analyses.
III. Q1 2024 ACTIVITY SUMMARY
A. Assignment to IRS Appeals (January 2024)
Following C&H's filing of the formal Protest on December 22, 2023, the IRS examination team transmitted the case file to the IRS Office of Appeals in accordance with standard administrative procedures. In January 2024, the case was assigned to Appeals Officer Noreen Castañeda, based in the IRS Appeals Office in Manhattan, New York.
Upon receipt of the assignment notification, C&H submitted a letter to Appeals Officer Castañeda on January 10, 2024, formally introducing the C&H engagement team, confirming the scope of C&H's power of attorney, and requesting the scheduling of an Appeals conference. In the letter, C&H proposed several available dates in late February 2024 for the conference, noting the complexity of the transfer pricing issues involved and the advisability of conducting the conference in person rather than by telephone. C&H also requested that the Appeals Officer identify any preliminary questions or areas of particular interest in advance of the conference to facilitate efficient preparation.
B. Pre-Conference Preparation (January – February 2024)
The pre-conference preparation phase was one of the most intensive periods of the engagement. C&H and WVG devoted substantial resources to preparing for the Appeals conference, drawing upon the extensive factual record developed during the examination phase and the arguments articulated in the Protest.
Strategic Planning. The internal appeals strategy memorandum was circulated to the C&H engagement team and PPC's in-house stakeholders on December 1, 2023. A detailed hazards-of-litigation analysis was completed on December 5, 2023, evaluating the strengths and weaknesses of both PPC's and the IRS's positions on each of the three issues under examination and assessing the likely outcome ranges in the event the case were to proceed to the United States Tax Court. Based on this analysis, a settlement authority memorandum was prepared and approved by PPC management on December 10, 2023. The settlement authority established a target resolution at 10–15% of the IRS's proposed $380.4 million net adjustment, with an outside ceiling of 20% of the proposed adjustment, reflecting the C&H team's assessment that PPC's positions were well-supported and that the IRS's proposed adjustments were significantly overstated.
Economic Rebuttal. During January 2024, WVG prepared a comprehensive rebuttal of IRS Economist Dr. Alan Washburne's economic analysis. The rebuttal memorandum, authored by Dr. Helena Vasquez and Dr. Rohan Chakrabarti and dated January 2024, challenged several critical aspects of Dr. Washburne's methodology:
(i) CUT Selection Criteria: Dr. Washburne's comparable uncontrolled transaction ("CUT") analysis employed overly narrow selection criteria that excluded several highly comparable pharmaceutical license agreements, resulting in a distorted interquartile range that supported the IRS's proposed 11.0% royalty rate. WVG demonstrated that, when the selection criteria were applied consistently with applicable Treasury Regulations and OECD Transfer Pricing Guidelines, the interquartile range was 3.1% to 6.8%, with a median of 4.4%, well within the range of PPC's 4.5% royalty rate.
(ii) discount Rate Assumptions: Dr. Washburne employed a weighted average cost of capital ("WACC") of 7.2% in his discounted cash flow ("DCF") valuation of the pre-existing intangible property contributed by PPC to the CSA, which WVG demonstrated was inappropriately low in light of the risk profile of the intangible assets at issue. WVG's analysis supported a WACC of 9.8%, reflecting a more accurate assessment of the systematic and unsystematic risks associated with early-stage pharmaceutical intellectual property. The difference in discount rates produced a substantial divergence in present-value calculations, with the IRS's lower WACC inflating the valuation of the contributed intangibles from WVG's $312 million figure to the IRS's $852 million figure.
(iii) Projected Revenue Growth Rates: Dr. Washburne's revenue growth projections for the intangible property were based on assumptions that were inconsistent with the actual revenue trajectory observed during the post-CSA period and were not supported by contemporaneous analyst estimates or internal projections prepared at the time of the CSA's inception.
Pre-Conference Memorandum. C&H completed the pre-conference memorandum on February 15, 2024. This memorandum served as the comprehensive briefing document for the Appeals conference, summarizing the key legal and economic arguments, anticipating questions likely to be raised by Appeals Officer Castañeda, outlining the witness preparation completed to date, and detailing the conference logistics. The memorandum was circulated to all attendees on the PPC/C&H side for review and comment.
Witness Preparation. C&H conducted witness preparation sessions with two individuals who would be present at the Appeals conference:
• Marcus Whitfield, VP, Global Tax: Witness preparation session conducted on February 20, 2024, at C&H's Philadelphia offices. The session focused on Mr. Whitfield's familiarity with PPC's transfer pricing methodology, the CSA structure, PBI's operations and substance, and the Company's interaction with the IRS exam team during the IDR process. Mr. Whitfield was prepared to address factual questions regarding PPC's decision-making processes, the roles and responsibilities of PBI personnel, and the contemporaneous documentation supporting PPC's transfer pricing positions.
• Dr. Helena Vasquez, Managing Director, WVG: Witness preparation session conducted on February 22, 2024, at C&H's Philadelphia offices. The session focused on Dr. Vasquez's economic analyses, including her CUT analysis, CPM/TNMM benchmarking study, and DCF valuation of the PCT payment. Dr. Vasquez was prepared to respond to technical economic questions and to present the key findings of WVG's rebuttal of Dr. Washburne's analysis in a manner accessible to a non-economist Appeals Officer.
Conference Materials. C&H finalized the Appeals conference presentation in Northgate Services Inc. format, together with detailed talking points for each presenter. A comprehensive document binder was assembled with the following tabs:
• Tab 1: Protest (filed December 22, 2023)
• Tab 2: Exhibit A — CUT Analysis and Comparable License Agreements
• Tab 3: Exhibit B — CPM/TNMM Benchmarking Analysis
• Tab 4: Exhibit C — PCT DCF Valuation
• Tab 5: Exhibit D — PBI Economic Substance Evidence
• Tab 6: Exhibit E — Contemporaneous Transfer Pricing Documentation
• Tab 7: WVG Economic Analyses and Rebuttal Memorandum
• Tab 8: PBI Substance Evidence (supplemental)
• Tab 9: Legal Authorities
• Tab 10: Settlement Analysis
C. Appeals Conference (February 28, 2024)
The Appeals conference was held in person at the IRS Appeals Office in Manhattan, New York, on February 28, 2024. The conference was attended by the following individuals:
PPC / C&H Side:
• Leonard Cross, Responsible Partner, Calderwood & Harkness LLP
• Sylvia Hartwell, Billing Partner, Calderwood & Harkness LLP
• Garrett Simmons, Lead Associate, Calderwood & Harkness LLP
• Marcus Whitfield, VP, Global Tax, Penterra Pharmaceuticals Corp.
• Deborah Staines, General Counsel, Penterra Pharmaceuticals Corp.
• Dr. Helena Vasquez, Managing Director, Whitmore Valuation Group LLC
IRS Side:
• Noreen Castañeda, Appeals Officer
The conference lasted approximately five and one-half hours, including a working lunch break. C&H's presentation addressed all three issues that were the subject of the IRS's proposed adjustments:
Issue 1: CSA Cost-Sharing Ratios. C&H presented PPC's analysis demonstrating that the cost-sharing ratios employed in the CSA were consistent with the arm's-length standard and properly reflected the parties' respective reasonably anticipated benefits from the intangible development activities. PPC's position was supported by WVG's CPM/TNMM analysis testing PBI's operating margins against 22 comparable distributors and IP-holding companies, which confirmed that PBI's results fell within the interquartile range in all four tax years under examination. The IRS exam team's proposed increase of 8 to 12 percentage points per year in PBI's cost-sharing ratio was shown to be unsupported by the comparable data.
Issue 2: Legacy IP Royalty Rate. C&H presented the CUT analysis performed by WVG, demonstrating that PPC's 4.5% royalty rate for the Legacy IP was well within the interquartile range of 3.1% to 6.8% (median 4.4%) derived from 14 comparable pharmaceutical license agreements identified through a rigorous search process. The IRS exam team's proposed royalty rate of 11.0% was shown to be an outlier unsupported by any of the identified comparables and to be based on Dr. Washburne's flawed CUT selection methodology.
Issue 3: PBI Economic Substance / DEMPE Functions. C&H presented extensive evidence of PBI's economic substance and its performance of key development, enhancement, maintenance, protection, and exploitation ("DEMPE") functions with respect to the intangible property. The evidence presented included:
• PBI's growth from 52 employees at inception in 2012 to 185 employees by the end of the examination period, including scientists, regulatory affairs specialists, commercial operations managers, and senior management;
• A total of 42 board of directors meetings held in Dublin during the 2017–2020 period, demonstrating active governance and decision-making at the Irish entity level;
• Cumulative regulatory expenditures of €47.2 million incurred by PBI during the period, reflecting PBI's direct involvement in the regulatory approval process for PPC's products in international markets;
• PBI's occupancy of approximately 18,000 square feet of office space at Sandyford Business Park in Dublin, providing a substantial physical presence; and
• PBI's independent pricing decisions across 68 country markets, demonstrating commercial autonomy and meaningful economic activity.
PCT DCF Valuation. Dr. Vasquez presented WVG's DCF valuation of the pre-existing intangible property contributed by PPC to the CSA at inception, establishing that the PCT payment of $312 million fell within the arm's-length range of $278 million to $361 million when a WACC of 9.8% was applied. This directly rebutted the IRS's valuation of $852 million, which was based on the inappropriately low WACC of 7.2% employed by Dr. Washburne.
Contemporaneous Documentation and Penalty Defense. C&H presented PPC's defense against the proposed IRC § 6662(e) substantial valuation misstatement penalty, emphasizing that PPC had maintained contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP under IRC § 6662(e) penalty-protection standards. This documentation, which satisfied the requirements of Treas. Reg. § 1.6662-6(d), established a reasonable-cause defense and demonstrated PPC's good-faith effort to comply with the arm's-length standard.
Appeals Officer Responsiveness. Throughout the conference, Appeals Officer Castañeda was engaged, asked probing but fair questions, and appeared receptive to PPC's arguments, particularly with respect to the CUT analysis and the PBI substance evidence. At the conclusion of the conference, the Appeals Officer indicated that she would review the materials submitted and might request additional comparable license data to supplement her independent analysis. She did not indicate a specific timeline for resolution but expressed her intention to move the case forward expeditiously.
A post-conference summary memorandum documenting the conference proceedings, the Appeals Officer's questions and reactions, and C&H's assessment of the conference outcome was prepared by Garrett Simmons and circulated to the engagement team and PPC stakeholders on March 1, 2024.
D. Supplemental Submission to Appeals (March 8, 2024)
In response to Appeals Officer Castañeda's request during the February 28 conference for additional comparable license agreement data, C&H submitted a supplemental written submission from Leonard Cross to Appeals Officer Castañeda, dated March 8, 2024. The supplemental submission provided additional comparable license agreements identified through an updated search and updated benchmarking data that further corroborated the arm's-length nature of PPC's 4.5% royalty rate. The additional comparables were drawn from license agreements executed during the 2015–2020 period involving pharmaceutical intellectual property in therapeutic areas closely related to PPC's oncology and immunology franchises. The supplemental submission also included a brief cover memorandum contextualizing the additional data within the framework of WVG's original CUT analysis.
E. Settlement Offer (March 15, 2024)
On March 15, 2024, Appeals Officer Castañeda issued a formal settlement offer to PPC through C&H. The settlement offer proposed the following terms:
Total adjustment: $47.6 million across all four tax years, representing 12.51% of the IRS exam team's proposed net adjustment of $380.4 million. The year-by-year allocation of the adjustment was as follows:
Penalty abatement: Full abatement of the IRC § 6662(e) substantial valuation misstatement penalty. The proposed penalty had been approximately $15.98 million. Appeals accepted PPC's reasonable-cause defense and determined that PPC's contemporaneous transfer pricing documentation satisfied the requirements for penalty protection under IRC § 6662(e)(3)(B) and the applicable Treasury Regulations.
The settlement offer represented an outstanding result, falling squarely within the target resolution range of 10–15% of the proposed adjustment that had been established in PPC's settlement authority memorandum approved in December 2023.
F. Settlement Analysis and Client Approval (March 15–22, 2024)
Upon receipt of the settlement offer, C&H undertook a prompt and thorough analysis of its terms and financial implications.
Settlement Offer Analysis Memorandum. A detailed settlement offer analysis memorandum was prepared by Leonard Cross and Sylvia Hartwell, dated March 18, 2024, and transmitted to Marcus Whitfield, Deborah Staines, and Rajesh Iyer. The memorandum addressed the following key elements:
Tax Due on Settlement: The $47.6 million adjustment, when taxed at the applicable 21% corporate tax rate, results in additional federal income tax due of approximately $10.0 million. (The memorandum noted the blended rate applicable to tax year 2017 due to the Tax Cuts and Jobs Act transition, but for purposes of the overall analysis, the simplified computation at 21% was presented, with a more detailed year-by-year computation provided in an attached workpaper.)
Estimated Underpayment Interest: Underpayment interest was estimated at approximately $2.84 million, computed at the applicable federal underpayment rate under IRC § 6621 for the relevant periods from the original due dates of the returns through the anticipated payment date. A detailed interest computation workpaper was attached to the memorandum.
Total Cash Cost: The total estimated cash cost to PPC under the settlement was approximately $12.84 million ($10.0 million in tax plus $2.84 million in estimated interest plus $0 in penalties).
Comparison to Full Proposed Adjustment Exposure: The memorandum compared the settlement outcome to the full exposure under the IRS exam team's proposed adjustments:
• Proposed tax: $380.4 million × 21% = approximately $79.88 million
• Proposed penalty: approximately $15.98 million
• Total proposed exposure: approximately $95.86 million
• Settlement cash cost: approximately $12.84 million
• Savings: approximately $83.02 million (86.6% reduction)
FIN 48 / ASC 740-10 Impact: The memorandum analyzed the impact of the settlement on PPC's reserve for uncertain tax positions under ASC 740-10 (formerly FIN 48). Prior to the settlement, PPC had maintained a FIN 48 reserve of $62.4 million related to the Irish IP structure. Following execution of the settlement, the reserve would be reduced to $14.8 million, with the remaining reserve attributable to other uncertain tax positions not resolved by the settlement. The reserve reduction of $47.6 million would have a favorable impact on PPC's effective tax rate and financial statements.
Communications with PPC Management. On March 19, 2024, Leonard Cross communicated the financial impact analysis directly to CFO Rajesh Iyer in a telephone call, walking through the key elements of the settlement offer analysis memorandum and responding to questions from Mr. Iyer regarding the interest computation methodology and the FIN 48 reserve adjustment.
Client Approval. PPC management, including CFO Rajesh Iyer and CEO Catherine Falk, approved acceptance of the settlement offer on March 21, 2024. The approval was confirmed by Marcus Whitfield to Leonard Cross via email on March 21, 2024.
Formal Acceptance. A formal acceptance letter from Leonard Cross to Appeals Officer Castañeda, dated March 22, 2024, was submitted to the IRS Office of Appeals, communicating PPC's unconditional acceptance of the settlement offer and requesting preparation of the IRS Form 906 Closing Agreement.
G. Closing Agreement Execution (March 29, 2024)
The IRS Form 906 Closing Agreement was executed on March 29, 2024. The Closing Agreement was signed by Marcus Whitfield on behalf of Penterra Pharmaceuticals Corp. and by the appropriate officials of the IRS Office of Appeals. The Closing Agreement memorializes the following terms:
(i) The total settlement adjustment of $47.6 million allocated across tax years 2017 through 2020, as set forth in the table above;
(ii) The full abatement of the proposed IRC § 6662(e) substantial valuation misstatement penalty; and
(iii) The formal closure of the IRS examination of PPC's federal income tax returns for tax years 2017, 2018, 2019, and 2020 under case reference LB&I-NE-TP-2022-00641.
The execution of the Form 906 Closing Agreement on March 29, 2024, marks the official closure of the IRS examination and the conclusion of the active phase of this engagement.
IV. SUMMARY OF IRS PROPOSED ADJUSTMENTS VS. SETTLEMENT OUTCOME
A. IRS Proposed Adjustments (NOPA Dated October 12, 2023)
The IRS exam team's Notice of Proposed Adjustment, issued on October 12, 2023, proposed the following adjustments to PPC's taxable income for the four tax years under examination:
1. CSA Cost-Sharing Ratio Adjustments
The IRS proposed to increase PBI's share of total qualified cost-sharing payments under the CSA by 8 to 12 percentage points per year, resulting in the following adjustments:
2. Legacy IP Royalty Rate Adjustments
The IRS proposed to increase the intercompany royalty rate charged by PPC to PBI for PBI's license to the Legacy IP from PPC's reported rate of 4.5% to 11.0%, resulting in a 6.5 percentage point increase applied to PBI's sales of Legacy IP products:
3. Correlative Offset
The IRS applied a correlative offset of ($42,650,000) to avoid double-counting where the CSA cost-sharing adjustments and the royalty rate adjustments overlapped with respect to certain categories of income.
4. Net Proposed Adjustment and Penalty
The proposed penalty was computed as 20% of the additional tax attributable to the $380.4 million adjustment at the 21% corporate tax rate: $380,400,000 × 21% = $79,884,000 × 20% = approximately $15,977,000.
B. Settlement Outcome
The settlement achieved the following outcome:
C. Comparison Table
The following table presents a comprehensive comparison of the IRS's proposed exposure and the settlement outcome:
As reflected in the foregoing table, the settlement achieved a total reduction in PPC's exposure of approximately $83.0 million, or 86.6%, relative to the IRS exam team's fully proposed adjustment and penalty. The settlement adjustment of $47.6 million fell at the lower end of the 10–15% target range established in PPC's settlement authority memorandum, and the complete abatement of the proposed $15.98 million penalty represents an additional significant benefit.
V. EXAMINATION CHRONOLOGY (FULL MATTER TIMELINE)
The following chronology sets forth the key dates and events over the full course of the matter, from the establishment of PPC's Irish IP structure through the execution of the Closing Agreement:
VI. FINANCIAL SUMMARY
A. Professional Fees
The following is a summary of professional fees incurred over the full duration of the engagement (June 2022 through matter closure on March 29, 2024):
1. Calderwood & Harkness LLP — Legal Fees
Total C&H legal fees for the engagement: $5,837,420
This amount falls within the estimated fee range of $4.5 million to $7.0 million that was communicated to PPC at the commencement of the engagement and is consistent with the scope and complexity of the examination, which involved four tax years, three discrete transfer pricing issues, a contested NOPA, a formal Protest, and an Appeals conference resulting in settlement.
For reference, the 2022 standard billing rates for the primary C&H engagement team members at engagement commencement were as follows:
These rates were subject to annual adjustments for calendar years 2023 and 2024, consistent with C&H's standard rate adjustment policies and as disclosed to PPC at the time of each annual adjustment. Detailed billing summaries by timekeeper, by phase, and by quarter have been provided with each quarterly invoice throughout the engagement, and the final Q1 2024 billing summary accompanies this report under separate cover.
2. Whitmore Valuation Group LLC — Expert Fees
Total WVG expert fees for the engagement: $2,146,800
WVG's fees were billed at a blended rate of approximately $650 per hour and covered the full scope of WVG's economic services, including: (i) the CUT analysis of the Legacy IP royalty rate; (ii) the CPM/TNMM benchmarking analysis of PBI's cost-sharing ratios and operating margins; (iii) the DCF valuation of the PCT payment; (iv) the rebuttal of IRS Economist Dr. Washburne's analysis; (v) preparation for and attendance at the Appeals conference; and (vi) support for all submissions to the IRS during the IDR phase, the Protest, and the supplemental Appeals submission.
3. Thornbury & Keogh — Irish Tax Advisor Coordination Fees
Total Thornbury & Keogh fees for the engagement: €312,500 (approximately $341,200 at the average USD/EUR exchange rate of approximately $1.092/€)
Thornbury & Keogh served as PPC's Irish tax advisors and provided coordination services throughout the engagement, including advice on the Irish tax implications of the IRS examination, PBI's Irish tax filings and Knowledge Development box claims, and potential Mutual Agreement Procedure ("MAP") considerations under the U.S.-Ireland Income Tax Treaty.
Total Professional Fees:
B. Settlement Costs
Note: The tax computation presented above uses the 21% corporate tax rate for simplicity. For tax year 2017, a blended rate applies reflecting the transition from the 35% pre-TCJA rate to the 21% post-TCJA rate for portions of PPC's fiscal year. The year-by-year interest computation reflects the applicable federal underpayment rate under IRC § 6621 for the relevant periods from the original due dates of each return through the anticipated payment date. A detailed interest computation workpaper has been provided to PPC under separate cover.
C. Total Cost of Examination to PPC
D. FIN 48 / ASC 740-10 Impact
The reserve reduction of $47.6 million reflects the resolution of the IRS examination and the certainty provided by the executed Form 906 Closing Agreement. The remaining post-settlement reserve of $14.8 million relates to other uncertain tax positions associated with PPC's international operations that were not within the scope of the closed examination.
VII. KEY DELIVERABLES PRODUCED DURING Q1 2024
The following is a list of the major documents and deliverables produced by C&H, WVG, and/or PPC during Q1 2024 in connection with the Appeals phase and settlement of the examination:
1. IRS Economist Rebuttal Memorandum — Prepared by Dr. Helena Vasquez and Dr. Rohan Chakrabarti of Whitmore Valuation Group LLC, January 2024. Comprehensive rebuttal of IRS Economist Dr. Alan Washburne's CUT analysis, WACC assumptions, and revenue growth projections.
2. Appeals Pre-Conference Memorandum — Prepared by C&H, completed February 15, 2024. Detailed briefing document summarizing key arguments, anticipated questions, witness preparation status, and conference logistics.
3. Witness Preparation Memoranda:
(a) Marcus Whitfield preparation memorandum — February 20, 2024 (b) Dr. Helena Vasquez preparation memorandum — February 22, 2024
4. Appeals Conference Presentation — Northgate Services Inc. presentation and accompanying talking points used at the February 28, 2024, Appeals conference.
5. Post-Conference Summary Memorandum — Prepared by Garrett Simmons, dated March 1, 2024. Summary of conference proceedings, Appeals Officer questions and reactions, and C&H assessment of conference outcome.
6. Supplemental Submission to Appeals — Letter from Leonard Cross to Appeals Officer Castañeda, dated March 8, 2024, providing additional comparable license agreements and updated benchmarking data.
7. Settlement Offer Analysis Memorandum — Prepared by Leonard Cross and Sylvia Hartwell, dated March 18, 2024. Detailed analysis of settlement terms, tax and interest computations, comparison to proposed exposure, and FIN 48 / ASC 740-10 impact.
8. Financial Impact Analysis Workbook — Excel workbook detailing the year-by-year tax, interest, and penalty computations, FIN 48 reserve adjustment, and effective tax rate impact.
9. Settlement Acceptance Letter — Letter from Leonard Cross to Appeals Officer Castañeda, dated March 22, 2024, communicating PPC's formal acceptance of the settlement offer.
10. Draft Form 906 Closing Agreement — Draft prepared by C&H and circulated for review prior to execution.
11. Executed Form 906 Closing Agreement — Executed on March 29, 2024, by Marcus Whitfield on behalf of PPC and by IRS Appeals.
12. Updated FIN 48 Analysis — Post-Settlement — Prepared in March 2024, reflecting the impact of the settlement on PPC's ASC 740-10 reserve for uncertain tax positions.
All deliverables listed above are maintained in C&H's matter file and are subject to the attorney-client privilege and work-product doctrine protections discussed in Section XI of this report. Copies of all deliverables have been provided to PPC in the ordinary course during the engagement.
VIII. POST-CLOSURE ACTION ITEMS AND NEXT STEPS
Although the IRS examination has been formally closed, several post-closure action items remain for PPC's attention. C&H has identified the following items and, where applicable, has provided or will provide guidance to PPC and its other advisors.
A. Amended Return Filings
PPC is required to file amended federal income tax returns (Forms 1120X) for tax years 2017 through 2020 to reflect the $47.6 million settlement adjustment memorialized in the Form 906 Closing Agreement. An instructions memorandum detailing the specific line-item adjustments, the year-by-year allocation of the settlement adjustment, and the coordination between the amended federal returns and PPC's existing transfer pricing documentation was prepared by Garrett Simmons and provided to Marcus Whitfield on April 5, 2024.
PPC should coordinate with Crestfield & Associates LLP — specifically, engagement partner Martin Ogilvy and transfer pricing partner Susan Lam — for the preparation and filing of the amended returns. Crestfield served as PPC's independent auditor and return preparer for the tax years at issue and is familiar with the relevant schedules and supporting workpapers.
B. Interest Payment
The estimated underpayment interest of approximately $2.84 million is payable to the IRS concurrent with the filing of the amended returns. The interest computation workpaper prepared by C&H has been provided to PPC and should be reviewed and finalized by PPC's in-house tax team in coordination with Crestfield prior to payment. The interest computation is based on the applicable federal underpayment rate under IRC § 6621 for the relevant periods from the original due dates of the returns through the anticipated payment date. The final interest amount may vary slightly depending on the actual payment date.
C. State Tax Implications
The federal settlement adjustment may give rise to state income tax consequences in the jurisdictions in which PPC files state income tax returns. Of particular significance is the potential impact in New Jersey, PPC's state of headquarters and principal place of business, as well as in other states in which PPC has substantial nexus. The apportionment effects of the federal adjustment on PPC's state-level taxable income should be analyzed to determine whether amended state returns are required or advisable.
A separate memorandum on state tax implications, including an analysis of the apportionment effects and potential state-level amended return obligations, is being prepared by Leila Nazari and is expected to be provided to PPC by the target date of April 10, 2024.
D. Irish Tax Coordination
Coordination with Thornbury & Keogh (lead partner Ciarán Thornbury) regarding the Irish tax consequences of the U.S. settlement is an important post-closure action item. The settlement adjustment may have implications for PBI's Irish tax position, including the potential impact on PBI's claims under the Knowledge Development box ("KDB") regime, which provides for a reduced corporate tax rate of 6.25% on qualifying income derived from qualifying intellectual property assets.
In addition, consideration should be given to whether a Mutual Agreement Procedure ("MAP") request under Article 25 of the U.S.-Ireland Income Tax Treaty is warranted in order to avoid or mitigate double taxation arising from the U.S. settlement adjustment. If the settlement adjustment results in income being taxed by both the United States and Ireland without a corresponding adjustment to PBI's Irish tax liability, a MAP request would provide a mechanism for the competent authorities of the two countries to resolve the double taxation.
Leila Nazari communicated with Ciarán Thornbury on March 20, 2024, regarding the Irish-side impact of the settlement and the potential need for a MAP request. Thornbury & Keogh is expected to provide its preliminary analysis to C&H and PPC within the coming weeks.
E. Hargrove Credit Facility Notification
PPC should assess whether the settlement triggers any reporting obligations under the tax-indemnity or material-tax-event covenants contained in PPC's $1.5 billion revolving credit facility with Hargrove National Bank, N.A. (relationship manager Christine Bellucci). An analysis of the relevant covenant provisions was provided by C&H in a prior memorandum dated November 2023, when the IRS's proposed adjustments were first received. That analysis concluded that the proposed adjustments, and any likely settlement outcome, would fall well below the materiality thresholds specified in the credit agreement. The actual settlement outcome of $12.84 million in total cash cost confirms that conclusion, and it is not expected that any notification to Hargrove National Bank will be required. PPC's in-house legal team should nevertheless review the applicable provisions to confirm this assessment.
F. SEC Disclosure
PPC should update its SEC filings — including its Annual Report on Form 10-K and Quarterly Report on Form 10-Q — to reflect the resolution of the IRS examination, the reduction of the FIN 48 reserve from $62.4 million to $14.8 million, and the final settlement amount. The disclosures should address the settlement in the context of PPC's existing risk factor and contingency disclosures, as well as the ASC 740-10 disclosures in the notes to the financial statements.
C&H notes that Ridgeview Capital Management LP, which holds approximately 8.3% of PPC's outstanding common stock (managing partner Douglas Everett), is known to closely monitor ASC 740-10 disclosures by its portfolio companies. The disclosure language should be carefully crafted to accurately reflect the resolution while avoiding any implication of weakness in PPC's underlying transfer pricing methodology.
Leonard Cross communicated SEC disclosure considerations to General Counsel Deborah Staines in November 2023 in connection with the initial NOPA disclosure. Updated guidance regarding the settlement-specific disclosure language will follow in due course.
G. Going-Forward Transfer Pricing Recommendations
In light of the issues raised during the examination, C&H has identified several areas in which PPC's transfer pricing practices and documentation may benefit from enhancement for tax years 2021 forward. C&H will provide the following advisory deliverables:
(1) Transfer Pricing Advisory Memorandum: A comprehensive memorandum recommending adjustments to PPC's transfer pricing documentation, cost-sharing calculations, and PBI's operational substance for tax year 2021 and subsequent years. This memorandum will be prepared by Leonard Cross and is targeted for delivery by April 15, 2024.